Company intelligence / Profile preview

Spirosure

Pleasanton, California, United Statesngkntk.co.jp ↗

Ownership: Private
Development stage: Commercial

Overview

Spirosure developed non-invasive diagnostic devices to measure fractional exhaled nitric oxide (FeNO) as a biomarker for airway inflammation. Its lead product, Fenom PRO Point-of-Care Breath Analyzer, received CE Mark approval and was commercialized in Europe and India. The company was acquired by CAIRE in June 2020 and now operates as Caire Diagnostics Inc. There are no clinical trial results typical of drug development; instead, the company's success centers on regulatory approvals and market adoption of its devices.

Therapeutic areas: Pulmonology
Modalities: DeviceNon-pharmacological therapy
Industry: Metabolite Diagnostics

Drug pipeline

1 asset

Fenom Pro

Commercial

Indications: Asthma

Partnerships

NGK Spark Plug Co Ltd.CAIRENiterra Ventures

Beyond the preview

Go deeper on Spirosure.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Spirosure.

Explore the full profile